Potent MTH1 inhibitor (IC50
= 72 nM). Induces DNA damage and disrupts nucleotide pool homeostasis in cancer cells. Also attenuates colony formation of KRAS-mutated PANC1 cells in vitro
. Suppresses tumor growth ~50% in a colon cancer carcinoma xenograft model.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc
Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy.
Huber et al.